跳轉至內容
Merck
  • 'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.

'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.

Clinical medicine (London, England) (2014-08-08)
Christopher D Smith, Stefanie Robert
摘要

The use of novel psychoactive substances ('legal highs' or 'designer drugs') is increasing worldwide. Patients misusing such substances have been reported to experience severe or prolonged side effects requiring admission to acute or critical care wards. These complications can be life threatening if misdiagnosed or mismanaged. As physicians have traditionally had less involvement with the management of such patients compared with their colleagues in emergency departments an update in the management of such patients is indicated. Here we present a summary of the management of those novel substances with the potential for serious complications based on a review of current literature.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
哌嗪, ReagentPlus®, 99%
Supelco
γ-羟丁酸钠盐标准液 钠盐 溶液, 1.0 mg/mL in methanol (as salt), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
R(+)-卡西酮 盐酸盐 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
哌嗪, BioUltra, anhydrous, ≥99.0% (T)
Supelco
哌嗪 六水合物, analytical standard
Sigma-Aldrich
S(−)-Cathinone hydrochloride
哌嗪 六水合物, European Pharmacopoeia (EP) Reference Standard